Damora Therapeutics, Inc. (DMRA) stock
Close on Nov 12, 2026Market cap $1.36BP/E 5.5Yield 0.00%
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $1.36B
- P/E ratio
- 5.5
- Price to sales
- –
- Price to book
- 2.75
- Dividend yield
- 0.00%
- Free cash flow yield
- –
Fundamentals
- Net income
- -$291.68M
- EPS, diluted
- $3.98
- Book value per share
- $8.02
- Diluted shares
- 62M
Trading
- Previous close
- $23.25
- Open
- $23.04
- Day's range
- $21.83 – $23.05
- Volume
- 671,093
- Average volume (20 days)
- 500,130
- Index membership
- Russell 2000 (since Jun 2026), Russell 3000
- Beta (5 years)
- 0.89
- 52-week range
- $15.76 – $38.33
- RSI (14 days)
- 49.2
- Volatility (1 year)
- 99.3%
- Relative volume
- 1.30×
On 2 of our idea lists: Insiders buying the dip, Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | DMRA | S&P 500 | Difference | DMRA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.9% | -2.7% | +11.6 pts | ||
| 3 months | -28.9% | -1.7% | −27.1 pts | ||
| Year to date | -4.2% | +11.9% | −16.1 pts | ||
| 1 year | -6.6% | +12.0% | −18.6 pts | ||
| 3 years | +52.1% | +78.2% | −26.1 pts | +15.0% | +21.2% |
| 5 years | -75.2% | +73.2% | −148.4 pts | -24.3% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Damora Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Update
- Update
- Update
About Damora Therapeutics
Pharmaceutical Preparations
Damora Therapeutics, Inc. is a preclinical-stage biopharmaceutical company focused on discovering and developing therapies for hematologic disorders. The company's pipeline centers on treatments for myeloproliferative neoplasms, which are chronic bone marrow disorders driven by myeloid cell proliferation. Its primary development programs include DMR-001, DMR-002, and DMR-003, which are monoclonal antibody candidates designed to selectively target mutant calreticulin. These investigational therapies aim to treat patients diagnosed with essential thrombocythemia and myelofibrosis.
Company profile, executives and historyDamora Therapeutics stock: common questions
What is Damora Therapeutics's stock price?
DMRA closed at $22.05 on Nov 12, 2026, down 5.16% on the day. Over the past 52 weeks it traded between $15.76 and $38.33.
What is Damora Therapeutics's market cap?
Damora Therapeutics was worth $1.36B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is DMRA's P/E ratio?
DMRA trades at 5.5 times earnings, based on diluted earnings per share of $3.98 over fiscal 2025.
Does Damora Therapeutics pay a dividend?
No. Damora Therapeutics has not paid a cash dividend over the last twelve months.
How has DMRA stock performed over the past year?
Including dividends, DMRA returned -6.6% over the past year, against +12.0% for the S&P 500.
How many DMRA shares are sold short?
5M shares were sold short at the latest FINRA report, 9.22% of the float, or 10.7 days of average trading volume.
Who are Damora Therapeutics's competitors?
Companies most similar to Damora Therapeutics by business, industry and size include IRON, KROS, JBIO, FULC, PRLD.
See a number that looks wrong?